Dr. Laurencin: The future of regeneration we believe is in taking an "un-siloed" approach to thinking about regeneration. For instance, we have studied how cells interact with biomaterials with an eye toward understanding biocompatibility. We now have to more closely examine methods by which the physical and chemical makeup of cells can manipulate cellular activities. We have thought about developmental biology as a distinct field. We must think of morphogenesis and developmental biology as tools to integrate into the regenerative engineering armamentarium. It is with this open perspective toward fully integrating disparate technologies that we can achieve new science and new solutions.
Question: What are the significant bottlenecks in the regenerative engineering field limiting its development? How can we overcome those bottlenecks? Dr. Laurencin: There are a number of bottlenecks. I will touch upon a few. First, scientists and engineers by their nature are trained to master one area of endeavor. Study and mastery of multiple disparate fields are difficult, both in training and in practice. Second, funding agencies often have grant panels with individuals trained in specific subfields, making it difficult to appreciate the complexities involved in a convergence approach. Still, it is more difficult to fully explain a number of complex approaches in one grant application with page limits versus an application which delves into one area of science. Universities often grant promotion and tenure using criteria developed 50 years ago. The value of team science and the value of convergence approaches-working in a number of areas of science and engineering-are often not appreciated or rewarded.
Question: Since the concept of regenerative engineering is defined as the convergence of tissue engineering with advanced material science, stem cell science, and developmental biology, what was the toughest challenge for your team during integration of these distinct research fields? Dr. Laurencin: The biggest challenge is making it work! My strategy comes perhaps from my background in orthopedic surgery, where we often must repair and regenerate complex tissues. Our philosophy is that to a great extent we must respect and work with the body's own functions in the repair and regeneration process. Only then can we really achieve true regeneration.
Question: What are the important factors we should consider to translate regenerative engineering research into clinics? Dr. Laurencin: There are so many, but let me point out one. Our definition of regenerative engineering includes clinical translation. We believe that clinicians must be fully vested in the research and clinical translation process. For instance, our regenerative engineering team includes a physical medicine and rehabilitation clinical specialist. We recognize that rehabilitation protocols will be different for treatment of regenerative-engineered therapies versus the processes we currently use for normal injury repair. Having a specialist in that area is important in designing the clinical pathways so crucial for successful clinical outcomes. Dr. Laurencin: Regenerative engineering was borne from the need to create therapies to help people, to affect the lives of people, to bring hope, comfort, help, and eventually cures. My expectation is that we will achieve this.
Awards and Recognitions
Professor Anthony Atala, M.D., Ph.D. (Wake Forest University) was honored with the 2016 American Ingenuity Award in Life Science by Smithsonian Magazine. Since the Smithsonian Institution was established for the increase and diffusion of knowledge among men in 1846, the Smithsonian has been recognizing innovations for more than 150 years. The American Ingenuity Award is the most prestigious recognition, and Professor Atala was awarded for his pioneering work in regenerative medicine by developing living tissues and organs with patients' own cells using 3D printing to solve the transplant organ shortage.
Professor David Scadden, M.D. (Harvard University) was awarded the 2016 E. Donnall Thomas Lecture and Prize from the American Society of Hematology (ASH) for his pioneering research achievements in bone marrow and stem cell transplantation. This prize is named after the Nobel Prize laureate E. Donnall Thomas, MD, who was the past ASH president and recognizes significant discovery in the research field of hematology.
Professor The Swedish company Cellink launched a new userfriendly 3D printer named Bio X™ that can print human tissues, including the skin, heart, cartilage, and bone tissues that incorporate living cells. The printer head can offer useful features, such as temperature-controlling function and multiple types of extrusion methods. Cellink is expecting the Bio X can boost research in the field of life science and bioprinting.
Orthocell Ltd., a regenerative medicine company that is dedicated to providing innovative treatments for injuries related to tendon, cartilage, and soft tissues, announced a research collaboration with DePuy Synthes Products Inc., one of the Johnson & Johnson family of companies, to develop a nonsurgical stem cell approach (Ortho-ATI® autologous tenocyte implantation) for the regeneration of damaged tendons and ligaments. Their collaborative trials to evaluate Ortho-ATI therapy will be conducted with leading orthopedic surgeons in Australia, including Professor Allan Wang, M.D., Ph.D. (University of Western Australia).
Advancements in Academia
Scientists at Stanford University have identified abnormal mechanism of impairing bone regeneration in a diabetic mouse by analyzing determinants of skeletal stem cell function (2017)).
Scientists at Brigham and Women's Hospital, Harvard Medical School, developed a shear-thinning biomaterial, composed of gelatin and silicate nanoplatelets, for endovascular embolization which is expected to replace metallic coils in the clinic. This novel shear-thinning biomaterial is injectable through catheters and needles in a minimally invasive way and has hemostatic activity, while being able to withstand physiological pressures of vessels with in vivo stability. When this biomaterial was injected in a murine and porcine vasculature in vivo, the occlusion was induced in a controlled way without non-target embolization, suggesting a translational potential for endovascular embolization. This research was published in Science Translational Medicine (R.K. Avery et al. "An injectable shear-thinning biomaterial for endovascular embolization" Science Translational Medicine 8365 (2016)).
Views: Government and Public Policy
In December 2016, the 114th US Congress enacted the 21st Century Cures Act which authorized 6.3 billion dollars for funding National Institutes of Health (NIH), supporting biomedical research and drug development, and reducing opioid abuse. Of this, 4.8 billion dollars was allocated to NIH, particularly for research fields related to cancer and brain disease such as Alzheimer's. The 21st Century Cures Act also expedited the drug approval process of the Food and Drug Administration, particularly for new products on existing drugs. For example, according to circumstances, the act allows drug companies to provide summaries of data rather than full report of clinical trial. On December 13, 2016, President Obama signed the Cures Act to support the medical breakthroughs.
The Pentagon announced plans to establish the Advanced Regenerative Manufacturing Institute (ARMI) to engineer organs, headquartered in Manchester, New Hampshire. According to The Pentagon, the mission for ARMI is to "organize the current fragmented domestic capabilities in tissue biofabrication technology and better position the USA relative to global competition." ARMI will initially focus on the research related to 3D biofabrication technologies, bioreactors, high-throughput culture technologies, storage methods, realtime monitoring and sensing, detection technologies, and nondestructive evaluation, aiming to replace limbs and heal trauma injuries. ARMI will be the twelfth manufacturing hub under the Obama administration's manufacturing program. Seven of them are defense-related manufacturing centers led by The Pentagon.
